NF2 is an inclusion criterion in 5 clinical trials for schwannoma, of which 2 are open and 3 are closed. Of the trials that contain NF2 status and schwannoma as inclusion criteria, 2 are early phase 1 (1 open) and 3 are phase 2 (1 open) [4].

NF2 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain NF2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

NF2 is an inclusion criterion in 3 clinical trials for meningioma, of which 1 is open and 2 are closed. Of the trials that contain NF2 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (0 open) [4].

NF2 is an inclusion criterion in 2 clinical trials for malignant pleural mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain NF2 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for neurofibromatosis type 2, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and neurofibromatosis type 2 as inclusion criteria, 1 is phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NF2 is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].